Remnant Cholesterol - Focus CKD - Prof. Dr. Borge Nordestgaard (Copenhagen, Denmark) скачать в хорошем качестве

Remnant Cholesterol - Focus CKD - Prof. Dr. Borge Nordestgaard (Copenhagen, Denmark)

Prof. Børge G. Nordestgaard explains the importance of remnant cholesterol in atherosclerotic cardiovascular disease, focusing upon patients with chronic kidney disease and particularly upon novel epidemiological data from the Copenhagen General Population Study, which have recently been published in Arteriosclerosis, Thrombosis, and Vascular Biology, with Prof. Nordestgaard as corresponding author. Prof. Nordestgaard is Professor of Clinical Medicine at the University of Copenhagen, Denmark. He is chairing the Copenhagen General Population Study and steering committee member of the Copenhagen City Heart Study. Additionally Prof. Nordestgaard is President of the European Atherosclerosis Society (EAS). The interview was recorded on January 13th, 2025. Moderators: Prof. Dr. Florian Custodis (Saarbrücken, Germany), Prof. Dr. Dr. Stephan Schirmer (Kaiserslautern, Germany) and Prof. Dr. Gunnar Heine (Frankfurt, Germany). Articles discussed: Impaired Renal Function With Higher Remnant Cholesterol Related to Risk of Atherosclerotic Cardiovascular Disease: A Cohort Study. Elías-López D, Vedel-Krogh S, Kobylecki CJ, Wadström BN, Nordestgaard BG Arterioscler Thromb Vasc Biol 2024 doi: 10.1161/ATVBAHA.124.321387 Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Nielsen SF, Nordestgaard BG Eur Heart J 2016 doi: 10.1093/eurheartj/ehv641 Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. Rosenson RS, Gaudet D, Hegele RA, Ballantyne CM, Nicholls SJ, Lucas KJ, San Martin J, Zhou R, Muhsin M, Chang T, Hellawell J, Watts GF; ARCHES-2 Trial Team. N Engl J Med 2024 doi: 10.1056/NEJMoa2404147 Why do the Media report negative news about statins? Nordestgaard BG Eur Heart J. 2018 doi: 10.1093/eurheartj/ehx789 Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. Ballantyne CM, Vasas S, Azizad M, Clifton P, Rosenson RS, Chang T, Melquist S, Zhou R, Mushin M, Leeper NJ, Hellawell J, Gaudet D. N Engl J Med 2024 doi: 10.1056/NEJMoa2404143 Colchicine in Acute Myocardial Infarction. Jolly SS et al.; CLEAR Investigators. N Engl J Med 2024 doi: 10.1056/NEJMoa2405922 Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Nicholls SJ et al. Am Heart J 2024 doi: 10.1016/j.ahj.2024.05.002 The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease? Reeskamp LF, Tromp TR, Stroes ESG. Curr Opin Lipidol 2020 doi: 10.1097/MOL.0000000000000679 Effects of dalcetrapib in patients with a recent acute coronary syndrome. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators. N Engl J Med 2012 doi: 10.1056/NEJMoa1206797 Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. N Engl J Med 2019 doi: 10.1056/NEJMoa1812792 Effects of torcetrapib in patients at high risk for coronary events. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators. N Engl J Med 2007 doi: 10.1056/NEJMoa0706628 High Lipoprotein(a) as a Cause of Kidney Disease: A Population-Based Mendelian Randomization Study. Bay Simony S, Rørbæk Kamstrup P, Bødtker Mortensen M, Afzal S, Grønne Nordestgaard B, Langsted A. J Am Coll Cardiol 2024 doi: 10.1016/j.jacc.2024.08.059 Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. N Engl J Med 2022 doi: 10.1056/NEJMoa2210645